Omalizumab in persistent severe bakers’ asthma
Authors:
- M. OlivieriM. Olivieri
- C. A. BiscardoCBC. A. Biscardo
- S. TurriSTS. Turri
- L. PerbelliniLPL. Perbellini
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- GINA guidelines on asthma and beyond*Allergy, 2007
- Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthmaAllergy, 2007
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical & Experimental Allergy, 2004
- Development of the asthma control testJournal of Allergy and Clinical Immunology, 2004
- Measuring Quality of Life in AsthmaAmerican Review of Respiratory Disease, 1993